News

The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of…

The U.S. Food and Drug Administration has cleared the start of clinical trial testing of KT-621, Kymera Therapeutics’ oral therapy for chronic obstructive pulmonary disease (COPD) and other diseases marked by type 2 inflammation. KT-621 is designed to target STAT6, a protein involved in type 2 inflammation, which…

Ohtuvayre (ensifentrine), an inhaled therapy approved in the U.S. earlier this year for adults with chronic obstructive pulmonary disease (COPD), has been found to safely and effectively lead to clinical improvements among COPD patients regardless of disease severity, smoking history, and chronic bronchitis history. Chronic bronchitis is a…

Dry-powder corticosteroid inhalers, or those designed to have a low impact on climate, are as effective as those based on pressurized, metered doses at reducing the risk of poor outcomes in people with both chronic obstructive pulmonary disease (COPD) and asthma. A large study in Denmark found the two…

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils. Elevated eosinophils are a marker of type 2 inflammation, which is thought to contribute…

The voice of people with chronic obstructive pulmonary disease (COPD) becomes more pitched and sounds breathy or hoarse at the early stages of disease exacerbations, which are episodes when symptoms suddenly worsen, according to a pilot study where 28 patients were asked to record their voices every day for…

Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation, which contributes to lung inflammation. That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK…

DirectRx, a specialty pharmacy for people with chronic health disorders, is now part of the exclusive U.S. pharmacy network distributing Ohtuvayre (ensifentrine), a newly approved therapy for chronic obstructive pulmonary disease (COPD). The Verona Pharma therapy, with a list price of $2,950 for a monthly supply,…

A higher genetic risk for chronic obstructive pulmonary disease (COPD) is associated with reduced lung function starting in childhood, a study of more than 45,000 people across Europe shows. A person’s genetic makeup plays a key role in lung health early on, increasing the risk for COPD later in…

The U.S. Food and Drug Administration (FDA) has granted breakthrough designation to tezepelumab, an approved therapy for severe asthma, as an add-on maintenance treatment for moderate to very severe chronic obstructive pulmonary disease (COPD) marked by an eosinophilic profile. An eosinophilic profile refers to high blood levels of eosinophils,…